Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRVI - Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A


IEX Last Trade
9.05
-0.160   -1.768%

Share volume: 1,143,319
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$9.21
-0.16
-1.74%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 14%
Dept financing 23%
Liquidity 75%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
1.57%
1 Month
-4.54%
3 Months
1.80%
6 Months
12.84%
1 Year
-12.39%
2 Year
-58.14%
Key data
Stock price
$9.05
P/E Ratio 
-9.70
DAY RANGE
N/A - N/A
EPS 
-$0.99
52 WEEK RANGE
$4.52 - $11.56
52 WEEK CHANGE
-$0.12
MARKET CAP 
1.281 B
YIELD 
N/A
SHARES OUTSTANDING 
141.553 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,384,999
AVERAGE 30 VOLUME 
$3,008,551
Company detail
CEO: Carl W. Hull
Region: US
Website: maravai.com
Employees: 125
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri

Recent news